First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy

Media formats available:

Long-term efficacy and safety of intravenous iron in HF
Long-term efficacy and safety of intravenous iron in HF
AHA 2022
Long-term efficacy and safety of intravenous iron in HF
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
AHA 2022
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
- Robert J. Mentz, MD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
AHA 2022
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
- Prof. Pamela Douglas, MD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
- David Preiss, PhD

PACE-CME